Concept
Treatment Combination
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
"This all-oral combination is for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that has grown after at least one hormone therapy. In EMBER-3, people with ESR1 mutations went a median of 11.1 months before progression on the combination, vs 5.5 months on Inluriyo (imlunestrant) alone."
Related Ideas
- Imlunestrant Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References:
- Etcamah Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Blood Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- September Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways